Health Care M&A Weekly Deals, The Week Ending August 11, 2017
Articles written by Lisa Phillips:
Acquisition data from Q2:17 shows pharmaceutical deal volume continues its steep downward decline. (See chart)
Fresenius, a global leader in dialysis, brings dialysis into the home with a $2 billion deal.
A few CROs, like PRA Health Sciences, are turning to eHealth acquisitions to strengthen their data technology capabilities.
KKR & Co., through its portfolio company, is the second private equity firm to pay more than $2 billion for a medical transportation company in 2017.
Health Care M&A Weekly Deals, The Week Ending August 4, 2017
Deal makers took a break in July, judging by the lower deal volume and lower deal value posted in our preliminary data for the month. Compared with the previous month, deal volume dropped 20%, to 100 transactions, and deal value fell 49%, to $8.7 billion.
Financial buyers in healthcare services are interested in segments with unyielding demand and little medical risk. No wonder, then, that dental groups have become a major target for these investors, and we’ve got the data to prove it. .
Just a month ago, we reported on molecular-diagnostics firm Invitae (NYSE: NVTA), and its interest in the eHealth sector, following the acquisition of two digital health companies. In July, the company set its sights on other laboratory companies and announced two more acquisitions.
In late July, Laboratory Corp. of America Holdings (NYSE: LH) announced the 6th CRO deal to surpass the $1 billion mark this year. The $1.2 billion deal for Chiltern is its third announced transaction this year, having acquired Mount Sinai’s Clinical Outreach Laboratories (January) and Pathology Associates Medical Laboratories, LLC (February).